MedTrace Logo

Renal PK Study of LC350189

NCT04066712 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2020-09-21

No results posted yet for this study

Summary

This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the effect of renal impairment on the PK and PD of LC350189.

Conditions

  • Gout
  • Hyperuricemia

Interventions

DRUG

LC350189 200 mg

Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2020-09-12
Completion
2020-09-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04066712 on ClinicalTrials.gov